Ruxolitinib Versus Best Available Therapy in Patients With Glucocorticoid-Refractory Chronic Graft-Vs-Host Disease: Primary Findings From the Phase 3, Randomized REACH3 Study

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6 / 7
页数：2
相关论文
共 50 条
  • [31] Study Design of a Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate Ruxolitinib Over BAT in Patients with Corticosteroid-Refractory Chronic Graft vs Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation (REACH-3)
    Zeiser, Robert
    Ram, Ron
    Foley, Stephen Ronan
    Yeshurun, Moshe
    Locatelli, Franco
    Artz, Andrew
    Gadbaw, Brian
    Atienza, Edric
    Hollaender, Norbert
    Delaite, Patricia
    Teshima, Takanori
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S208 - S208
  • [32] THE PROBABILITY OF BEING IN RESPONSE: A NOVEL EFFICACY ENDPOINT FOR CHRONIC GRAFT VERSUS HOST DISEASE APPLIED TO THE REACH-3 STUDY OF RUXOLITINIB VERSUS BAT
    Hollaender, Norbert
    Glimm, Ekkehard
    Gauvin, Jennifer
    Stefanelli, Tommaso
    Zeiser, Robert
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 313 - 313
  • [33] PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB: RESULTS OF THE SIMPLIFY-2 STUDY
    Verstovsek, S.
    Vannucchi, A. M.
    Platzbecker, U.
    Cervantes, F.
    Gupta, V.
    Lavie, D.
    Passamonti, F.
    Winton, E. F.
    Dong, H.
    Kawashima, J.
    Maltzman, J. D.
    Kiladjian, J-J.
    Harrison, C. N.
    HAEMATOLOGICA, 2017, 102 : 320 - 321
  • [34] A Phase 3, Open-Label, Randomized Study Evaluating the Efficacy and Safety of Navitoclax Plus Ruxolitinib Versus Best Available Therapy in Patients with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)
    Dilley, Kimberley
    Harb, Jason
    Jalaluddin, Muhammad
    Hutti, Jessica E.
    Potluri, Jalaja
    BLOOD, 2020, 136
  • [35] A novel approach to visualize clinical benefit of therapies for chronic graft versus host disease (cGvHD): the probability of being in response (PBR) applied to the REACH3 study
    Hollaender, Norbert
    Glimm, Ekkehard
    Gauvin, Jennifer
    Stefanelli, Tommaso
    Zeiser, Robert
    BONE MARROW TRANSPLANTATION, 2024, 59 (01) : 12 - 16
  • [36] Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).
    Harrison, Claire N.
    Vannucchi, Alessandro M.
    Platzbecker, Uwe
    Cervantes, Francisco
    Gupta, Vikas
    Lavie, David
    Passamonti, Francesco
    Winton, Elliott F.
    Dong, Hua
    Kawashima, Jun
    Maltzman, Julia D.
    Kiladjian, Jean-Jacques
    Verstovsek, Srdan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] A novel approach to visualize clinical benefit of therapies for chronic graft versus host disease (cGvHD): the probability of being in response (PBR) applied to the REACH3 study
    Norbert Hollaender
    Ekkehard Glimm
    Jennifer Gauvin
    Tommaso Stefanelli
    Robert Zeiser
    Bone Marrow Transplantation, 2024, 59 : 12 - 16
  • [38] A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
    Ong, Jian Chun Matthew
    Than, Hein
    Tripathi, Sandeep
    Gkitzia, Christina
    Wang, Xiaojun
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [39] A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
    Jian Chun Matthew Ong
    Hein Than
    Sandeep Tripathi
    Christina Gkitzia
    Xiaojun Wang
    Cost Effectiveness and Resource Allocation, 21
  • [40] The Probability of Being in Response (PBR): A Novel Efficacy Endpoint for Chronic Graft Versus Host Disease (GvHD) Applied to the Reach-3 Study of Ruxolitinib Versus BAT
    Hollaender, Norbert
    Glimm, Ekkehard
    Gauvin, Jennifer
    Stefanelli, Tommaso
    Zeiser, Robert
    BLOOD, 2022, 140 : 10521 - 10522
12345